Advertisement
Organisation › Details
Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. *
Start | 2000-12-01 established | |
Group | Alligator Bioscience (Group) | |
Predecessor | University of Lund (Lund University) | |
Industry | FIND® technology (Fragment INduced Diversity) | |
Industry 2 | mitazalimab (ADC-1013) | |
Person | Norlén, Per (Alligator Bioscience –202103 CEO) | |
Person 2 | Benson, Peter (Sunstone Capital 200705– Managing Partner Life Science Ventures) | |
Region | Lund | |
Country | Sweden | |
City | 223 81 Lund | |
Tel | +46-46-286-4280 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | C: 51 to 100 (2019-12-31) |
Currency | SEK | |
Annual sales | 4,352,000 (sales, net, consolidated (2020) 2020-12-31) | |
Profit | -143,296,000 (2020-12-31) | |
Cash | 103,342,000 (2020-12-31) | |
* Document for »About Section«: Alligator Bioscience AB. (1/18/18). "Press Release: Alligator Bioscience Appoints New VP Business Development". Lund. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Alligator Bioscience (Group)
- [1] Alligator Bioscience AB. (4/15/21). "Press Release: Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy". Lund....
- [2] Alligator Bioscience AB. (2/12/20). "Press Release: Alligator Bioscience AB Year-end Report January-December 2019"....
- [3] Alligator Bioscience AB. (7/31/19). "Press Release: Alligator Bioscience Regains Global Rights from Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)". Lund....
- [4] Alligator Bioscience AB. (7/21/17). "Press Release: Aptevo Therapeutics and Alligator Bioscience Announce Plans to Co-develop Novel Bispecific Antibody for Tumor-directed Immunotherapy". Seattle, WA & Lund....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top